Sign in
Taking peopleNo phase

Plasma Host-Microbe Proteomics to Predict Complications in High-risk Febrile Neutropenia

Key facts

Who runs it
Instituto de Investigación Biomédica de Salamanca
Where
Spain3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
350 people, planned
Started
9 Jun 2026
Expected to end
Jan 2029
Type of study
Observational
Treatments tested
  • Plasma and DNA sample collection for proteomic and genomic analysis
Record updated
15 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Adults (≥18 years)
  • Written informed consent provided by patient or legal representative
  • Diagnosis of hematologic malignancy under induction chemotherapy, post-allogeneic hematopoietic stem cell transplantation, or CAR-T therapy
  • High-risk febrile neutropenia (ANC ≤ 100 cells/mm³, expected duration ≥ 7 days, or significant comorbidities)
  • Fever defined as oral temperature ≥38.3 °C once or ≥38.0 °C for ≥1 hour
  • Hospitalized or requiring immediate admission at the time of FN diagnosis; ´- Initial uncomplicated clinical presentation, with no previous infection or colonization by multidrug-resistant bacteria
  • Eligible for initial monotherapy with broad-spectrum empirical antibiotic
  • Availability for serial plasma sampling and clinical follow-up

Who cannot take part

  • Any condition preventing safe participation or reliable sample collection
  • Age <18 years
  • Low-risk FN according to MASCC/CISNE criteria
  • Initial sample collected after antibiotic administration
  • Decline or inability to provide informed consent
  • Fever induced by noninfectious causes (considered as adjustment factor, not exclusion)

This trial is currently available in Spain.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Febrile neutropenia (FN) is a common oncologic emergency in patients with hematologic malignancies, associated with high morbidity and mortality. Early identification of patients at higher risk of complications such as sepsis or septic shock is critical to optimize antimicrobial management.

Read full original descriptionShow less

This study aims to characterize the human and microbial plasma proteome using high-resolution mass spectrometry to identify biomarker combinations ("combitypes") capable of predicting complications in oncohematologic patients with FN.

A cohort of 350 adult patients with high-risk FN and initially uncomplicated clinical presentation will be enrolled across three tertiary hospitals. Plasma samples will be collected at fever onset (before antibiotic initiation) and after 48 hours. Proteomic data will be integrated with clinical information using multivariate and machine learning models to develop a predictive model for complications.

The group in the trial

  • High-risk FN cohort

    Adult onco-hematologic inpatients meeting inclusion criteria; two plasma draws at fever onset and 48 h.

    Treatment: Plasma and DNA sample collection for proteomic and genomic analysis

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter Prospective Observational Study on the Plasma Proteomic Profiling of Human and Microbial Proteins for the Early Identification of Biomarker Combinations (Combitypes) Associated With Complications in Oncohematologic Patients With Febrile Neutropenia
Record updated
15 June 2026